In crisis? Call 988 then Press 1, text 838255, or chat at VeteransCrisisLine.net

The VA told Congress on November 18, 2026 that roughly 180,000 veterans might qualify for psychedelic-assisted mental health treatment if the FDA approves it, and that it has already picked 10 VA facilities for an initial rollout. But lawmakers pressed VA officials hard at the House Veterans’ Affairs Subcommittee on Health hearing over staffing, funding and who gets treated first, according to Military Times, States Newsroom and Stars and Stripes.

Here is what came out of the hearing, what it means for you, and what you can do now. Veteran Services is not affiliated with VA. For background, see our guide to mental health and PTSD, or search the directory for PTSD resources.

The big numbers from the hearing

  • About 180,000 veterans might qualify under preliminary screening criteria, VA estimates. Military Times notes this figure is based on screening criteria from existing research, not confirmed eligibility for an approved treatment.
  • About 2.1 million veterans in VA health care have diagnoses involving PTSD, major depressive disorder or treatment-resistant depression, VA officials said.
  • 10 VA facilities have been identified for the first phase, including sites for clinical care and clinician training. VA has not released the full list publicly.
  • 21 active psychedelic-treatment studies were underway at VA as of September, including research on MDMA and psilocybin, according to Military Times.
  • Six to eight hours: how long a single supervised dosing session can last, on top of preparation and follow-up care.

Lawmakers’ biggest questions: staff, money and “who goes first”

Lawmakers from both parties backed the idea but questioned whether VA is ready. Rep. Julia Brownley (D-Calif.), the subcommittee’s ranking member, asked whether VA will hire more staff so current mental health providers aren’t overloaded if treatments are approved “in the next several months,” States Newsroom reported.

Andrew Gradison, a senior adviser to the Veterans Health Administration, called the treatments “extremely labor intensive.” Military Times reported that officials acknowledged VA’s fiscal 2027 budget included no dedicated funding request for rolling out the treatments, though they said existing resources are sufficient. Lawmakers pointed to a September VA inspector general report that found 58% of reporting VA facilities identified severe shortages of psychologists.

Rep. Maggie Goodlander (D-N.H.) asked, “Who goes first, and who decides?” Gradison said decisions would be guided by medical ethics, clinical eligibility and patient safety, with VA’s most experienced clinicians providing treatment first. “If we save one veteran’s life next year from these treatments, it’s worth it,” he told lawmakers.

Rep. Herb Conaway (D-N.J.) noted that most of the initial sites appear to be on the coasts and asked about coverage in the Southeast. Dr. Ilse Wiechers of the Veterans Health Administration said the sites were chosen because they were judged most likely to succeed early, and VA plans to build on that experience. Military Times reported VA plans to expand as more clinicians are trained and is developing standards for referring veterans to community providers.

Rep. Morgan Luttrell (R-Texas), a longtime advocate, urged caution: “If you mess up this much, this goes away forever.”

What VA promised Congress within 30 days

Gradison agreed to send lawmakers a staffing plan within 30 days, covering how many clinicians are needed, where they would come from and projected costs, according to Military Times. He also committed to giving committee members the list of the 10 initial facilities.

Veterans groups push to speed up research

The Veterans of Foreign Wars, Disabled American Veterans and the Special Forces Foundation testified in support of faster research and fewer barriers for treatments that prove safe and effective, Stars and Stripes reported. “Veterans deserve access to treatments proven safe and effective through rigorous scientific evaluation,” said Naomi Mathis, DAV’s deputy legislative national director. Stars and Stripes also reported that DAV has launched an online information platform called MindScapes on the science, benefits and risks of these therapies.

Important reality check

  • Nothing is approved yet. These drugs, including MDMA, psilocybin and ibogaine, remain Schedule I controlled substances under federal law. Stars and Stripes reported that several are moving toward potential FDA approval in 2027 following an April 2026 executive order.
  • Eligibility isn’t set. Who qualifies will depend on which therapies, if any, the FDA approves and the restrictions that come with approval.
  • Access will start small. Officials acknowledged geographic access will be limited in the first phase.

What you can do now

  • Talk to your VA mental health provider about evidence-based PTSD and depression treatments available today, and ask whether any VA research studies are enrolling near you.
  • Be cautious about unregulated treatment. Using these substances outside approved research or clinical settings carries legal and medical risks. Talk with a qualified clinician before making any treatment decision, especially if you take other medications.
  • Find support near you. Search our directory for mental health resources or read our guide to substance use recovery.
  • Catch up on the backstory in our earlier report: House Panel to Weigh Psychedelic Therapy for Veterans as HHS Funds Ibogaine PTSD Research.

If you are struggling right now, you do not have to wait for new treatments. Call 988 then Press 1, text 838255, or chat at VeteransCrisisLine.net, any time, day or night.

Sources

Veteran Services is an independent directory. It is not affiliated with the U.S. Department of Veterans Affairs, the FDA, or Congress, and it does not provide medical or legal advice. Talk with a qualified health care provider before making treatment decisions, and confirm details on the official pages linked above. Read our privacy policy and disclaimer.

Leave a Reply

Your email address will not be published. Required fields are marked *